Grading of tumor regression in non-small cell lung cancer : morphology and prognosis.

@article{Junker2001GradingOT,
  title={Grading of tumor regression in non-small cell lung cancer : morphology and prognosis.},
  author={Klaus Junker and K Langner and Folker Klinke and Ulrich Bosse and M. Thomas},
  journal={Chest},
  year={2001},
  volume={120 5},
  pages={
          1584-91
        }
}
OBJECTIVE Different types of multimodality therapy, including chemoradiotherapy and surgery, increasingly are being used for the treatment of patients with locally advanced non-small cell lung cancer (NSCLC; stages IIIA and IIIB). In this context, the applicability of a morphologic regression grading and its prognostic value were investigated. PATIENTS AND METHODS In a multicenter phase II trial, 54 patients with locally advanced NSCLC received neoadjuvant bimodality treatment (ie, two cycles… 

Figures and Tables from this paper

Prognostic Impact of Histopathologic Response after Neoadjuvant Chemotherapy in Stage IIIA Non-small Cell Lung Cancer

The extent of tumor regression induced by neoadjuvant chemotherapy is a critical issue for successful therapeutic approach in patients with stage IIIA NSCLC and the presence of marked tumor regression (regression grade III-IV) is predictive for superior survival time.

Histologic Assessment of Non–Small Cell Lung Carcinoma after Neoadjuvant Therapy

Tumor size reduction by radiologic assessment, when compared with histologic regression, did not reveal a statistically significant association, however, a positive correlation was found between extent of fibrosis and radiologic estimate of size reduction.

Histopathological Grading of Tumor Regression in Lung Cancer

The central and pivotal role that pathologists will play in predicting the prognostic relevance of neoadjuvant therapy in lung cancer is clearly delineated, as more specific multimodal agents and targeted therapies are on the horizon, the pathologist should be called upon to assess their successes or failures.

Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification

Histomorphologic tumor regression and lymph node status (ypN) were significant prognostic parameters for patients with complete resections (R0) following neoadjuvant radiochemotherapy for esophageal cancer.

Neoadjuvant chemoradiation with paclitaxel/carboplatin for selected Stage III non-small-cell lung cancer: long-term results of a trimodality Phase II protocol.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

  • A. PataerN. Kalhor S. Swisher
  • Medicine
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2012
Histopathologic assessment of resected specimens after neoadjuvant chemotherapy could potentially have a role in addition to pathologic stage in assessing prognosis, chemotherapy response, and the need for additional adjuvant therapies.

Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer

Considering its convenience and operability in clinical application, a 10% threshold RVT value can be used for prognostic evaluation of LNM andPrimary tumors of squamous cell carcinoma histology; further studies are needed to confirm the optimal cutoff value for primary tumors of adenocarcinoma.

The Multidisciplinary Approach in Stage III Non-Small Cell Lung Cancer over Ten Years: From Radiation Therapy Optimisation to Innovative Systemic Treatments

It is found that the choice of radical treatment impacts on outcome, thus suggesting the importance of appropriate staging at diagnosis, patient selection, and of the multidisciplinary approach in the decision-making process.
...

References

SHOWING 1-10 OF 24 REFERENCES

Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer.

  • M. ThomasC. Rübe K. Junker
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
This trimodality approach is feasible and results in encouraging 3-year survival rates in prognostically unfavorable patients with stage III NSCLC.

Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials.

The authors have observed pathologic complete responses in approximately 12% of advanced NSCLC patients treated with preoperative MVP chemotherapy, which predicts excellent survival and functional level and should be considered a major end point in the evaluation of preoperative chemotherapy programs.

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.

  • R. BurkesR. Ginsberg J. Cooper
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
It is concluded that MVP is an effective but toxic chemotherapeutic regimen for limited NSCLC; the median survival seems to be prolonged; and the role of induction chemotherapy followed by surgery in stage IIIA N2 NSCLc requires a phase III randomized trial to compare it with other treatment modalities.

Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial.

  • W. EberhardtH. Wilke S. Seeber
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
This intensive multimodality treatment is feasible and demonstrates high efficacy in prognostically unfavorable LAD-NSCLC subgroups with high R0 rates and improved long-term survival compared with historical controls.

Neoadjuvant chemotherapy in marginally resectable stage III M0 non‐small cell lung cancer: Long‐term follow‐up in 41 patients

While neoadjuvant CAP followed by radiotherapy appears to improve survival, more effective chemotherapy along with randomized studies are needed to determine the role of initial chemotherapy in marginally resectable NSCLC.

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

  • K. AlbainV. Rusch D. Gandara
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1995
The strongest predictor of long-term survival after thoracotomy was absence of tumor in the mediastinal nodes at surgery, and this trimodality approach was feasible in this Southwest Oncology Group (SWOG) study.

Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III M0 non-small cell lung cancer.

The patients with chemotherapy, chest irradiation, and surgical resection had a low incidence of local in-chest failure, but distant failure was still a major problem, and there were no statistically significant survival differences between patients not having thoracotomy and those who hadThoracotomy.

Revisions in the International System for Staging Lung Cancer.

Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.